Source | Study objectives, design and analysis | Reported relapse rates | |
---|---|---|---|
Rapaport et al. [1] | Escitalopram continuation treatment to prevent relapse; a multi-center, placebo controlled, randomized withdrawal study; 36-week randomized treatment; Kaplan-Meier estimate and log-rank test as primary statistical analysis | Escitalopram | 26.0%* (109) |
 |  | Placebo | 40.0%* (116) |
Keller et al. [2] | Long-term efficacy and tolerability of gepirone ER; a multi-center, placebo controlled, randomized withdrawal study; 40-44 weeks of randomized treatment; chi-square test; Kaplan-Meier estimate and log-rank test as Primary statistical analysis | Gepirone ER | 20.6% (26/126) |
 |  | Placebo | 28.2% (35/124) |
Kamijima et al.[3] | Efficacy, safety and tolerability of sertraline in the prevention of relapse; a multicenter, placebo controlled, randomized withdrawal study; 16-week randomized treatment; Kaplan-Meier estimate and log-rank test as primary statistical analysis | Sertraline | 08.5% (10/117) |
 |  | Placebo | 19.5% (23/118) |
Perahia et al. [4] | Efficacy, safety and tolerability of duloxetine in the prevention of relapse; A multi-center, placebo controlled, randomized withdrawal study; 26-week randomized treatment; Kaplan-Meier estimate, log-rank test as primary statistical analysis | Duloxetine | 17.4% (23/132) |
 |  | Placebo | 28.5% (39/137) |
Kocsis et al. [5] | Long-term efficacy and safety of venlafaxine ER in preventing recurrence; a multi-center, placebo controlled, randomized withdrawal study; 12 months randomized treatment; Kaplan-Meier estimate and log-rank test as primary statistical analysis | Venlafaxine ER | 23.1%* (129) |
 |  | Placebo | 42.0%* (129) |